Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.40 |
| ▸ | KHK | P50053 | 8/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758308 | 1.00 | GRM2 (0.40) | GRM2KHKHTR6USP2ALDH1A1 | |
| SCHEMBL8574854 | 0.84 | TSHR (0.37) | KHKHTR6ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL8413871 | 0.81 | GAA (0.40) | KHKALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3760567 | 0.74 | ACHE (0.38) | HSD17B10 | |
| SCHEMBL4608571 | 0.69 | FADS1 (0.40) | HTR6NSD3MEN1NPC1RAB9A | |
| SCHEMBL4608568 | 0.69 | FADS1 (0.40) | HTR6NSD3MEN1NPC1RAB9A | |
| SCHEMBL4597271 | 0.69 | DRD2 (0.45) | HTR6MEN1KMT2A | |
| SCHEMBL8417143 | 0.68 | MAPT (0.36) | ALDH1A1MEN1NPC1KMT2A | |
| Hydrochloric Acid SCHEMBL8876143 | 0.67 | MAPT (0.38) | ALDH1A1MEN1NPC1KMT2A | |
| SCHEMBL11217206 | 0.67 | KHK (0.62) | KHKMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | GRM2 1044/4885KHK 4218/4885HTR6 2051/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | GRM2 1044/4885KHK 4218/4885HTR6 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.